SEARCH

SEARCH BY CITATION

References

  • 1
    Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De Vos R, Van Den Oord JJ, Collen D, Mulligan RC. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994; 368: 41924.
  • 2
    Bugge TH, Flick MJ, Danton MJ, Daugherty CC, Romer J, Dano K, Carmeliet P, Collen D, Degen JL. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci USA 1996; 93: 5899904.
  • 3
    Singh I, Burnand KG, Collins M, Luttun A, Collen D, Boelhouwer B, Smith A. Failure of thrombus to resolve in urokinase-type plasminogen activator gene-knockout mice: rescue by normal bone marrow-derived cells. Circulation 2003; 107: 86975.
  • 4
    Gurewich V, Emmons F, Pannell R. Spontaneous clot lysis in whole human plasma by endogenous tissue type and urokinase type plasminogen activators: demonstration of a promoting effect by t-PA and by platelets on urokinase. Fibrinolysis 1988; 2: 1439.
  • 5
    Moir E, Booth NA, Bennett B, Robbie LA. Polymorphonuclear leucocytes mediate endogenous thrombus lysis via a u-PA-dependent mechanism. Br J Haematol 2001; 113: 7280.
  • 6
    Pannell R, Gurewich V. Activation of plasminogen by single-chain urokinase or by two-chain urokinase – a demonstration that single-chain urokinase has a low catalytic activity (pro-urokinase). Blood 1987; 69: 226.
  • 7
    Ellis V, Scully MF, Kakkar VV. Plasminogen activation by single-chain urokinase in functional isolation. A kinetic study. J Biol Chem 1987; 262: 149985003.
  • 8
    Lijnen HR, Van Hoef B, Nelles L, Collen D. Plasminogen activation with single-chain urokinase-type plasminogen activator (scu-PA). Studies with active site mutagenized plasminogen (Ser740[RIGHTWARDS ARROW]Ala) and plasmin-resistant scu-PA (Lys158[RIGHTWARDS ARROW]Glu). J Biol Chem 1990; 265: 52326.
  • 9
    Wun TC, Ossowski L, Reich E. A proenzyme form of human urokinase. J Biol Chem 1982; 257: 72628.
  • 10
    Ichinose A, Fujikawa K, Suyama T. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 1986; 261: 34869.
  • 11
    Romisch J, Vermohlen S, Feussner A, Stohr H. The FVII activating protease cleaves single-chain plasminogen activators. Haemostasis 1999; 29: 2929.
  • 12
    Kilpatrick LM, Harris RL, Owen KA, Bass R, Ghorayeb C, Bar-Or A, Ellis V. Initiation of plasminogen activation on the surface of monocytes expressing the type II transmembrane serine protease matriptase. Blood 2006; 108: 261623.
  • 13
    Kobayashi H, Schmitt M, Goretzki L, Chucholowski N, Calvete J, Kramer M, Gunzler WA, Janicke F, Graeff H. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). J Biol Chem 1991; 266: 514752.
  • 14
    Goretzki L, Schmitt M, Mann K, Calvete J, Chucholowski N, Kramer M, Gunzler WA, Janicke F, Graeff H. Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L. FEBS Lett 1992; 297: 11218.
  • 15
    Nauland U, Rijken DC. Activation of thrombin-inactivated single-chain urokinase-type plasminogen activator by dipeptidyl peptidase I (cathepsin C). Eur J Biochem 1994; 223: 497501.
  • 16
    Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002; 22: 13819.
  • 17
    Jang IK, Gold HK, Ziskind AA, Fallon JT, Holt RE, Leinbach RC, May JW, Collen D. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. Circulation 1989; 79: 9208.
  • 18
    Robbie LA, Booth NA, Croll AM, Bennett B. The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis. Thromb Haemost 1993; 70: 3016.
  • 19
    Fay WP, Eitzman DT, Shapiro AD, Madison EL, Ginsburg D. Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and -independent mechanisms. Blood 1994; 83: 3516.
  • 20
    Gurewich V, Pannell R. A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity. Thromb Res 1986; 44: 21728.
  • 21
    Levi M, Biemond BJ, Van Zonneveld AJ, Ten Cate JW, Pannekoek H. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992; 85: 30512.
  • 22
    Deguchi K, Murashima S, Shirakawa S, Soria C, Soria J, Dunn F, Tobelem G. The potentiating effect of platelet on plasminogen activation by tissue plasminogen activator. Thromb Res 1985; 40: 85361.
  • 23
    Ouimet H, Freedman JE, Loscalzo J. Kinetics and mechanism of platelet-surface plasminogen activation by tissue-type plasminogen activator. Biochemistry 1994; 33: 29706.
  • 24
    Plow EF, Freaney DE, Plescia J, Miles LA. The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. J Cell Biol 1986; 103: 241120.
  • 25
    Hall SW, Humphries JE, Gonias SL. Inhibition of cell surface receptor-bound plasmin by alpha 2-antiplasmin and alpha 2-macroglobulin. J Biol Chem 1991; 266: 1232936.
  • 26
    Loza JP, Gurewich V, Johnstone M, Pannell R. Platelet-bound prekallikrein promotes pro-urokinase-induced clot lysis: a mechanism for targeting the factor XII dependent intrinsic pathway of fibrinolysis. Thromb Haemost 1994; 71: 34752.
  • 27
    Lenich C, Liu JN, Gurewich V. Thrombin stimulation of platelets induces plasminogen activation mediated by endogenous urokinase-type plasminogen activator. Blood 1997; 90: 357986.
  • 28
    Booth NA, Anderson JA, Bennett B. Platelet release protein which inhibits plasminogen activators. J Clin Pathol 1985; 38: 82530.
  • 29
    Silverstein RL, Leung LL, Harpel PC, Nachman RL. Platelet thrombospondin forms a trimolecular complex with plasminogen and histidine-rich glycoprotein. J Clin Invest 1985; 75: 206573.
  • 30
    Kannemeier C, Feussner A, Stohr HA, Weisse J, Preissner KT, Romisch J. Factor VII and single-chain plasminogen activator-activating protease: activation and autoactivation of the proenzyme. Eur J Biochem 2001; 268: 378996.
  • 31
    McWilliam NA, Robbie LA, Barelle CJ, Adey G, Prasad S, Bennett B, Booth NA. Evidence for an active fibrinolytic system in normal human bone marrow. Br J Haematol 1996; 93: 1706.
  • 32
    Mutch NJ, Moore NR, Wang E, Booth NA. Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI. J Thromb Haemost 2003; 1: 20007.
  • 33
    Okada Y, Tsuda Y, Tada M, Wanaka K, Hijikata-Okunomiya A, Okamoto U, Okamoto S. Development of plasma kallikrein selective inhibitors. Biopolymers 1999; 51: 4150.
  • 34
    Longstaff C, Whitton CM. A proposed reference method for plasminogen activators that enables calculation of enzyme activities in SI units. J Thromb Haemost 2004; 2: 141621.
  • 35
    Petersen LC. Kinetics of reciprocal pro-urokinase/plasminogen activation – stimulation by a template formed by the urokinase receptor bound to poly(D-lysine). Eur J Biochem 1997; 245: 31623.
  • 36
    Press W, Teukolsky S, Vetterling W, Flannery B. Numerical Recipes: the Art of Scientific Computing, 3rd edn. New York: Cambridge University Press, 2007: 44286.
  • 37
    Dixon M. The determination of enzyme inhibitor constants. Biochem J 1953; 55: 1701.
  • 38
    Sancho E, Tonge DW, Hockney RC, Booth NA. Purification and characterization of active and stable recombinant plasminogen-activator inhibitor accumulated at high levels in Escherichia coli. Eur J Biochem 1994; 224: 12534.
  • 39
    Methot N, Rubin J, Guay D, Beaulieu C, Ethier D, Reddy TJ, Riendeau D, Percival MD. Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing. J Biol Chem 2007; 282: 2083646.
  • 40
    Bugge TH, Flick MJ, Daugherty CC, Degen JL. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev 1995; 9: 794807.
  • 41
    Rijken DC, Sakharov DV. Molecular transport during fibrin clot lysis. Fibrinolysis Proteolysis 2000; 14: 98113.
  • 42
    Ellis V, Scully MF, Kakkar VV. Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J Biol Chem 1989; 264: 21858.
  • 43
    Jiang Y, Pannell R, Liu JN, Gurewich V. Evidence for a novel binding protein to urokinase-type plasminogen activator in platelet membranes. Blood 1996; 87: 277581.
  • 44
    Longstaff C. Plasminogen activation on the cell surface. Front Biosci 2002; 7: d24455.
  • 45
    Collen D, Zamarron C, Lijnen HR, Hoylaerts M. Activation of plasminogen by pro-urokinase. II. Kinetics. J Biol Chem 1986; 261: 125966.
  • 46
    Liu JN, Pannell R, Gurewich V. A transitional state of pro-urokinase that has a higher catalytic efficiency against glu-plasminogen than urokinase. J Biol Chem 1992; 267: 1528992.
  • 47
    Behrendt N, List K, Andreasen PA, Dano K. The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation. Biochem J 2003; 37: 27787.
  • 48
    Vaughan DE, Van Houtte E, Collen D. Urokinase binds to platelets through a specific saturable, low affinity mechanism. Fibrinolysis 1990; 4: 1416.
  • 49
    Ellis V, Whawell SA, Werner F, Deadman JJ. Assembly of urokinase receptor-mediated plasminogen activation complexes involves direct, non-active-site interactions between urokinase and plasminogen. Biochemistry 1999; 38: 6519.
  • 50
    Miles LA, Plow EF. Binding and activation of plasminogen on the platelet surface. J Biol Chem 1985; 260: 430311.
  • 51
    Adelman B, Rizk A, Hanners E. Plasminogen interactions with platelets in plasma. Blood 1988; 72: 15305.
  • 52
    Miles LA, Hawley SB, Baik N, Andronicos NM, Castellino FJ, Parmer RJ. Plasminogen receptors: the sine qua non of cell surface plasminogen activation. Front Biosci 2005; 10: 175462.
  • 53
    PRIMI Trial Study Group. Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. PRIMI Trial Study Group. Lancet 1989; 22: 8638.
  • 54
    Pannell R, Gurewich V. Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. Blood 1986; 67: 121523.
  • 55
    Manchanda N, Schwartz BS. Interaction of single-chain urokinase and plasminogen activator inhibitor type 1. J Biol Chem 1995; 270: 200325.
  • 56
    Liu JN, Gurewich V. Fragment E-2 from fibrin substantially enhances pro-urokinase-induced Glu-plasminogen activation. A kinetic study using the plasmin-resistant mutant pro-urokinase Ala-158-rpro-UK. Biochemistry 1992; 31: 631117.
  • 57
    Fleury V, Lijnen HR, Angles-Cano E. Mechanism of the enhanced intrinsic activity of single-chain urokinase-type plasminogen activator during ongoing fibrinolysis. J Biol Chem 1993; 268: 185549.
  • 58
    Lijnen HR, Zamarron C, Blaber M, Winkler ME, Collen D. Activation of plasminogen by pro-urokinase. I. Mechanism. J Biol Chem 1986; 261: 12538.